129
Participants
Start Date
May 28, 2018
Primary Completion Date
January 31, 2026
Study Completion Date
July 31, 2026
Radiation
70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
Cisplatin
100 mg/m2 days 1, 22, 43 concurrently with RT
Durvalumab
Given in concurrent and adjuvant phase
Tremelimumab
ARM CLOSED TO ACCRUAL - 2019
Cliniques Universitaires Saint-Luc, Brussels
Clinique St. Elizabeth, Namur
University Hospital of Gent, Ghent
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
University Hospital Ramon y Cajal, Madrid
Complejo Hospitalario de Navarra, Pamplona
University Clinical Hospital of Valencia, Valencia
University Hospital of Antwerp, Edegem
University Hospital Leuven, Leuven
AZ Sint Augustinus, Wilrijk
Cross Cancer Institute, Edmonton
CancerCare Manitoba, Winnipeg
QEII Health Sciences Centre, Halifax
Health Sciences North, Greater Sudbury
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
University Health Network, Toronto
The Jewish General Hospital, Montreal
The Research Institute of the McGill University, Montreal
CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
University Hospital Vall dHebron, Barcelona
Hospital Duran i Reynals, Barcelona
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK